Topical Transdermal Administration of Supramolecular Self-Assembled Carnosine for Anti-Melanin and Anti-Aging.
Level 5 - mechanism / opinion, no new human data
Preclinical laboratory research (in silico, in vitro, and in vivo) with uncharacterized preliminary clinical testing
PubMed 39279568 · doi:10.1002/adhm.202401960
What was done
Researchers investigated a supramolecular complex formed by the self-assembly of L-carnosine, acetyl carnosine, and decarboxy carnosine. They used molecular dynamics simulations and free-energy calculations to assess structural equilibrium and transdermal penetration mechanisms. Biological and aesthetic effects were evaluated using anti-photoaging and anti-glycation cell models, in vivo measurements of advanced glycation end products (AGEs), and cell and clinical whitening efficacy assessments.
What was found
The abstract reports no numerical values, sample sizes, or statistical metrics. Supramolecular carnosine was reported to show greater transdermal skin reactivity than L-carnosine by lowering lipid matrix interfacial resistance. In cell models, it upregulated Nrf2 expression, activated melanocyte antioxidant defense, and inhibited receptor for advanced glycosylation end products (RAGE) expression. In vivo, it reduced AGE levels, and preliminary clinical tests reported whitening efficacy.
Why it matters
Supramolecular assembly may address the limited skin penetration of conventional carnosine, offering a potential formulation strategy for topical anti-aging and cosmetic applications.
Limits
No quantitative data, error ranges, or statistical significance levels are provided in the abstract. Methodological details for the in vivo and clinical efficacy tests—including sample size, subject demographics, control interventions, and study duration—are entirely omitted.
Cited by
- partial A 2024 trial found that carnosine acts as a geroprotector via the NRF2 pathway and provides direct free radical scavenging and anti-inflammatory effects.